<DOC>
	<DOCNO>NCT01448187</DOCNO>
	<brief_summary>The aim study describe characteristic patient treat Iressa ( particularly age , gender , phenotype , histology stage disease , line treatment previous treatment , smoke history , condition initiation treatment ( presence EGFR-activating mutation ) evaluate impact treatment health population concern term morbidity mortality ( clinical benefit , safety , ... ) quality life</brief_summary>
	<brief_title>Descriptive Pharmacoepidemiological Study Patients Treated With Iressa</brief_title>
	<detailed_description>Descriptive pharmacoepidemiological study patient treat Iressa</detailed_description>
	<criteria>Patients treat Iressa Patient include therapeutic trial comprise protocol use Iressa Patient include therapeutic trial ( HurietSerusclat Act ) Patient refuse participate study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Lung cancer , France</keyword>
</DOC>